16,054 Shares in Harmony Biosciences Holdings, Inc. $HRMY Purchased by Callan Family Office LLC

Posted by Brian Himes on Aug 26th, 2026

Callan Family Office LLC acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,054 shares of the company’s stock, valued at approximately $585,000.

Other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after purchasing an additional 643 shares during the period. Allworth Financial LP lifted its holdings in shares of Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after buying an additional 602 shares during the period. Leonteq Securities AG acquired a new stake in shares of Harmony Biosciences in the 4th quarter valued at approximately $30,000. National Bank of Canada FI acquired a new stake in shares of Harmony Biosciences in the 3rd quarter valued at approximately $40,000. Finally, Clearstead Advisors LLC boosted its stake in shares of Harmony Biosciences by 145.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after buying an additional 699 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of recent analyst reports. Weiss Ratings raised Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. UBS Group restated a “neutral” rating and set a $37.00 target price on shares of Harmony Biosciences in a research report on Wednesday, August 5th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research report on Thursday, July 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $39.00 price target on shares of Harmony Biosciences in a research note on Wednesday, August 5th. Finally, Needham & Company LLC increased their price target on shares of Harmony Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $45.50.

Check Out Our Latest Research Report on Harmony Biosciences

Harmony Biosciences Stock Performance

Shares of HRMY opened at $38.95 on Wednesday. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87. The stock has a market cap of $2.27 billion, a P/E ratio of 12.65, a PEG ratio of 0.36 and a beta of 0.96. The company has a current ratio of 3.48, a quick ratio of 3.45 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $36.51 and a two-hundred day moving average of $32.74.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, beating the consensus estimate of $0.96 by $0.32. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. The business had revenue of $261.28 million for the quarter, compared to analyst estimates of $250.77 million. During the same period in the prior year, the business earned $0.92 earnings per share. The company’s quarterly revenue was up 30.3% on a year-over-year basis. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current fiscal year.

Harmony Biosciences Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.